Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Temporarily Halts Nevo Stent Trial, Citing Needed Catheter Improvements

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson has suspended enrollment in its NEVO II trial comparing its next-generation Nevo stent to Abbott's market-leading Xience V stent, citing needed improvements to the balloon catheter component of the system, the firm announced Oct. 19.

You may also be interested in...



And Then There Were Three: J&J/Cordis Exits Drug-Eluting Stent Market

The first company to enter the drug-eluting stent market will now be the first to depart.

And Then There Were Three: J&J/Cordis Exits Drug-Eluting Stent Market

The first company to enter the drug-eluting stent market will now be the first to depart.

J&J Nevo Stent Inhibits Tissue Proliferation Better Than Boston Sci’s Liberté

Johnson & Johnson/Cordis' Nevo next-generation sirolimus-eluting coronary stent inhibits tissue proliferation better than Boston Scientific's Taxus Liberté paclitaxel-eluting stent at six months, according to data from the NEVO RES-Elution I study unveiled May 19 at the EuroPCR meeting in Barcelona

Topics

UsernamePublicRestriction

Register

MT029527

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel